Background

Sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), hereditary hemoglobinopathies, arise from mutations in the beta-globin gene. SCD patients constantly bear severe pain, multi-organ damage, and stroke risk due to vaso-occlusive crises (VOC) caused by blocked microvessels. In contrast, TDT patients have relied on red blood cell transfusions every 2–4 weeks throughout their lives because they cannot produce normal hemoglobin. However, repeated blood transfusions can lead to fatal iron overload in the body, damaging heart and liver function. To overcome the limitations of bone marrow transplantation, which makes it difficult to find immunologically matched donors, autologous hematopoietic stem cell gene therapy has been developed. Exagamglogene autotemcel (hereinafter exa-cel), a CRISPR-Cas9-based therapeutic, has been recognized for its efficacy in adolescents aged 12 and older and adults. However, long-term damage accumulates silently from childhood before the age of 10. This was because there was an urgent need for clinical evidence to establish the efficacy of early gene correction in pediatric patients aged 5–11, before the disease leads to permanent organ failure.

Key Findings

This paper, published in the New England Journal of Medicine (NEJM), analyzes the results of multi-national phase 3 clinical trials (CLIMB THAL-141, CLIMB SCD-151) involving pediatric patients aged 5 to 11 treated with exa-cel. Researchers collected the infant's hematopoietic stem cells and injected CRISPR protein complexes via electroporation. The gene scissors precisely target the erythroid-specific enhancer of the BCL11A gene, which is responsible for suppressing gamma-globin expression. Once this suppression mechanism is released, the cells synthesize large amounts of fetal hemoglobin (HbF) to restore deficient functions. In the evaluable patient group following 16 months of follow-up, the treatment response rate was 100%. All 8 TDT patients have completely discontinued transfusions for at least 12 months, with hemoglobin levels remaining stably above recommended levels. All 8 patients with sickle cell disease also demonstrated a complete absence of acute vaso-occlusive crises for over 12 months. Conversely, significant safety issues arising from chemotherapy conditioning cast a large shadow. Due to high-dose busulfan administered to clear existing bone marrow, all patients experienced Grade 3 or higher adverse events. Notably, despite pharmacokinetic dose adjustments, severe hepatic veno-occlusive disease (VOD) developed in two pediatric patients with TDT. One of the affected children eventually died due to complications from busulfan-induced liver VOD.

Meaning and Prospects

These results demonstrate that the early introduction of gene editing can fundamentally alter the life trajectory of pediatric patients with hemoglobinopathies. It has proven the clinical value of preemptively preventing irreversible organ damage from solidifying in adulthood by intervening during school age. However, the high toxicity of the conditioning regimen that led to Hwan's death starkly revealed the vulnerabilities faced by in vitro gene editing platforms. Currently, the CRISPR gene scissors themselves boast high target gene cleavage efficiency. In contrast, the pre-treatment process for securing the in vivo bone marrow space remains stuck at the level of highly toxic chemotherapy drugs developed decades ago. Busulfan not only causes long-term gonadal failure but also poses the risk of permanent infertility and secondary cancer in pediatric patients. This is the background why development of non-genotoxic conditioning techniques must proceed alongside improvements in gene editing performance. The biotech industry is accelerating the development of conditioning agents based on antibody-drug conjugates (ADCs) that target the c-Kit (CD117) receptor on hematopoietic stem cells. The in vivo technique of directly correcting within the body using lipid nanoparticles, bypassing extracellular manipulation and cytotoxic drugs, has also emerged as a future alternative. Overcoming the limitations of exorbitant drug costs and complex manufacturing facility infrastructure is expected to ensure treatment accessibility.